Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee: SGLT-2 Inhibitors and Diabetic Ketoacidosis

    Basic Details
    Date
    Thursday, January 17, 2019
    Medical Product
    canagliflozin
    dapagliflozin
    empagliflozin
    sitagliptin
    sodium-glucose cotransporter-2 (SGLT-2) inhibitor
    Health Outcome(s)
    diabetic ketoacidosis